Natural Product (NP) Details

General Information of the NP (ID: NP3552)
Name
Spiramycin
Synonyms
spiramycin; 8025-81-8; ST075006; C43H74N2O14; Prestwick_121; Prestwick2_000745; Prestwick3_000745; BPBio1_000804; SCHEMBL5032756; AKOS015896378; 2-[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-[5-(4,5-dihydroxy-4,6-dimethyloxan-2-yl)oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde; K430; SR-01000872632; SR-01000872632-1; Spiramycin, European Pharmacopoeia (EP) Reference Standard; Spiramycin from Streptomyces sp., VETRANAL(TM), analytical standard; Spiramycin, Pharmaceutical Secondary Standard; Certified Reference Material; 2-[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-[5-(4,5-dihydroxy-4,6-dimethyloxan-2-yl)oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-1-oxacyclohexadeca-11,13-dien-7-yl]acet; 2-{(2S,3S,14S,1R,4R,8R,15R)-2-[5-(4,5-dihydroxy-4,6-dimethyl(2H-3,4,5,6-tetrah ydropyran-2-yl)oxy)-4-(dimethylamino)-3-hydroxy-6-methyl(2H-3,4,5,6-tetrahydro pyran-2-yl)oxy]-14-[5-(dimethylamino)-6-me; 2-{(2S,3S,14S,1R,4R,8R,15R)-2-[5-(4,5-dihydroxy-4,6-dimethyl(2H-3,4,5,6-tetrah ydropyran-2-yl)oxy)-4-(dimethylamino)-3-hydroxy-6-methyl(2H-3,4,5,6-tetrahydro pyran-2-yl)oxy]-14-[5-(dimethylamino)-6-methyl(2H-3,4,5,6-tetrahydropyran-2-yl )oxy]-4-hydroxy-3-; thyl(2H-3,4,5,6-tetrahydropyran-2-yl )oxy]-4-hydroxy-3-methoxy-8,15-dimethyl-6-oxo-7-oxacyclohexadeca-10,12-dienyl} ethanal
    Click to Show/Hide
Species Origin Streptomyces ambofaciens ...     Click to Show/Hide
Streptomyces ambofaciens
SuperKingdom: Bacteria
Phylum: Actinobacteria
Class: Actinomycetia
Order: Streptomycetales
Family: Streptomycetaceae
Genus: Streptomyces
Species: Streptomyces ambofaciens
Disease Bacterial infection [ICD-11: 1A00-1C4Z] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absporption
Caco-2 Permeability
 -5.737
 
MDCK Permeability
 -5.15
 
PAMPA
 +++
 
HIA
 - - -
 
Distribution
VDss
 0.071
 
PPB
 53.1%
 
BBB
 - - -
 
Metabolism
CYP1A2 inhibitor
 - - -
CYP1A2 substrate
 - - -
CYP2C19 inhibitor
 - - -
CYP2C19 substrate
 +++
CYP2C9 inhibitor
 - - -
CYP2C9 substrate
 - - -
CYP2D6 inhibitor
 - - -
CYP2D6 substrate
 - - -
CYP3A4 inhibitor
 - - -
CYP3A4 substrate
 - - -
CYP2B6 inhibitor
 - - -
CYP2B6 substrate
 - - -
CYP2C8 inhibitor
 - - -
HLM Stability
 -
 
Excretion
CLplasma
 3.984
 
T1/2
 4.633
Toxicity
DILI
 +++
 
Rat Oral Acute Toxicity
 - - -
 
FDAMDD
 - - -
 
Respiratory
 - - -
 
Human Hepatotoxicity
 ++
 
Ototoxicity
 +++
 
Drug-induced Nephrotoxicity
 +++
 
Drug-induced Neurotoxicity
 - - -
 
Hematotoxicity
 - - -
 
Genotoxicity
 -
 
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++). 2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C43H74N2O14
PubChem CID
6419898
Canonical SMILES
CC1CC=CC=CC(C(CC(C(C(C(CC(=O)O1)O)OC)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)O)(C)O)N(C)C)O)CC=O)C)OC4CCC(C(O4)C)N(C)C
InChI
1S/C43H74N2O14/c1-24-21-29(19-20-46)39(59-42-37(49)36(45(9)10)38(27(4)56-42)58-35-23-43(6,51)41(50)28(5)55-35)40(52-11)31(47)22-33(48)53-25(2)15-13-12-14-16-32(24)57-34-18-17-30(44(7)8)26(3)54-34/h12-14,16,20,24-32,34-42,47,49-51H,15,17-19,21-23H2,1-11H3/b13-12+,16-14+/t24-,25-,26?,27?,28?,29+,30?,31-,32+,34?,35?,36?,37?,38?,39+,40+,41?,42?,43?/m1/s1
InChIKey
ACTOXUHEUCPTEW-JMRHEKERSA-N
CAS Number
CAS 8025-81-8
TTD Drug ID
D0F5OR
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Nitazoxanide      Bowel habit change     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model 6-8 weeks old Swiss strain albino mice were used in this study.
                    Experimental
                    Result(s)		 SP-metronidazole gave the foremost effect on both mice survival rate and parasite load in the liver, spleen and brain.
Target and Pathway
Target(s) Bacterial 23S ribosomal RNA (Bact 23S rRNA)  Molecule Info  [3]
References
Reference 1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Reference 2 Effect of nitazoxanide and spiramycin metronidazole combination in acute experimental toxoplasmosis. Heliyon. 2020 Apr 16;6(4):e03661.
Reference 3 The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51.
 Download Picture         KEGG Link